Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Casdozokitug - Coherus BioSciences/Surface Oncology

Next Previous
Drug Profile

Casdozokitug - Coherus BioSciences/Surface Oncology

Alternative Names: Anti-IL-27 antibody - Coherus BioSciences; casdozo; CHS-388; IL-27 Blocking Antibody - Coherus BioSciences; SRF-388

Latest Information Update: 23 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Surface Oncology
  • Developer Coherus BioSciences; Merck & Co; Roche; Surface Oncology
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin-27 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Non-small cell lung cancer; Renal cell carcinoma

Most Recent Events

  • 23 Dec 2024 9432543 - KDM updated, dev line added for unknown location can change to specific once mentioned in the trial NCT06679985, trial initiation date taken from the MR, FE completed
  • 18 Dec 2024 Phase-II clinical trials in Liver cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in USA (IV) (NCT06679985)
  • 03 Dec 2024 Coherus Biosciences plans a phase II trial for Liver cancer (First-line therapy, Combination therapy, Inoperable/unresectable, Late-stage disease, Metastatic disease) in Q4 2024 (NCT06679985)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top